/C O R R E C T I O N -- Alteon Inc./
02 February 2006 - 5:14AM
PR Newswire (US)
In the news release, Alteon (AMEX:ALT) Provides Corporate Update,
issued earlier today by Alteon Inc. over PR Newswire, we are
advised by the company that the first bullet point should be
disregarded as it contained erroneous information. The complete,
corrected first bullet follows: * Alteon plans to pursue
development of lead compound alagebrium in high potential
cardiovascular indications such as heart failure, after recent data
presented at the American Heart Association (AHA) Scientific
Sessions in November 2005 demonstrated continued positive results
of alagebrium in patients with cardiovascular disease. The AHA
presentations included data from the Phase 2a PEDESTAL study in
diastolic dysfunction in heart failure with impaired ejection
fraction, as well as positive results from a Phase 2a study in
endothelial function. Alteon is in the process of preparing an IND
specifically in heart failure in order to expand its clinical
program in this therapeutic area. Any continued development of
alagebrium by the Company is contingent upon Alteon entering into
strategic collaboration agreements for this product candidate
which, among other things, would be required to include funding for
product development. PRNewswire -- Feb. 1 DATASOURCE: Alteon Inc.
Copyright
Ishares Diversified Alternatives Trust (AMEX:ALT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Ishares Diversified Alternatives Trust (AMEX:ALT)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Ishares Diversified Alternatives Trust (American Stock Exchange): 0 recent articles
More Alteon News Articles